Cytomos

Cytomos is a biotechnology company that develops cell analysis solutions for the biopharma industry. The company offers a novel cell analysis platform, AuraCyt, which enables unbiased, single-cell analysis without the need for labels. The AuraCyt platform monitors multiple cell features simultaneously and collects data on intrinsic cellular properties in near-real-time, unbiased, consistent, and accurate cell analytics. The technology enables pharmaceutical companies to accelerate biological drug discovery and development processes by up to six months faster than conventional methods by allowing critical decision-making earlier in the process. The platform is unique in its ability to measure cellular physiology based on intrinsic single-cell properties without requiring cell labeling reagents, making it a low-cost and scalable alternative to current cell analysis systems. 
The company's flagship product, Celledonia, launched in June 2024, is a benchtop cell analyzer built on the company’s patented AuraCyt platform that significantly enhances single-cell analysis for biological drug discovery, development processes, and biologics manufacturing.